Showing 119 of 119on this page. Filters & sort apply to loaded results; URL updates for sharing.119 of 119 on this page
JANX007 / Janux Therapeutics
My Janx007 Trial 2025. | Advanced Prostate Cancer
Janux Expands Phase 1b Trials for JANX007 in mCRPC
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update ...
Janux Advances JANX007 to Phase 1b in Prostate Cancer, Targeting ...
Janux Therapeutics, Inc. - JANX007 Poster, dated May 2-5, 2022 - EX-99. ...
JANX007 for Prostate Cancer Clinical Trial 2024 | Power
My JANX007 trial experience | Advanced Prostate Cancer
Janux Therapeutics Interim Clinical Data For JANX007 in mCRPC - YouTube
Prostate Cancer UCLA Clinical Trial | Study of JANX007 in Subjects With ...
Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In ...
Janux | T Cell Immuno-oncology | PSMA-TRACTr (JANX007)
如何理解前药肿瘤特异性释放_行业新闻-博康生物工程（山东）有限公司
Janux大涨67%：PSMA/CD3前抗体取得突破疗效 Armstrong 2024年12月2日， Janux Therapeutics ...
如何理解前药肿瘤特异性释放医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
美股龙虎报：VISTA停试验求卖身，一年一针的减肥药日涨270% 数据新进展：PSMA/CD3前抗体JANX007处于1期治疗mCRPC的中期 ...
前抗体技术：Cytomx沉沦，Janux异军突起 Armstrong 2024年3月11日，Cytomx Therapeutics 公布 ...
股价暴涨229%、募资1.75亿美元！Janux公布两款双抗积极临床数据医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
如何理解前药肿瘤特异性释放-MedSci.cn
酶切依赖型激活的Pro-TCE前药平台的思路、临床表现及在肿瘤中的应用_生物器材网
前抗体再掀波澜：Janux大涨230%，Cytomx涨36% Armstrong 2024年2月26日， Janux Therapeutics ...
Janux股价翻倍：PSMA/CD3双抗初步临床获得积极数据 Armstrong 2024年2月26日， Janux Therapeutics ...
Janux Therapeutics Stock Craters After ‘Positive’ Cancer Data. Why It’s ...
Janux Therapeutics Announces FDA Clearance of Investigational New Drug ...
TCE 前药核心策略解析：酶切依赖型激活平台（Janux/Vir/ 默沙东 / Zymeworks）及临床进展
Janux研发日：全面布局前抗体实体瘤TCE Armstrong 2025年7月24日， Janux Therapeutics 举办研发日活动 ...
JANX007临床数寤 - 2025年05月 - 行业研究数据 - 小牛行研
slide8
slide9
Preliminary Success for Janux Therapeutics’ Prostate and Solid Cancer ...
前列腺癌：唤醒"沉睡"的T细胞--T细胞衔接器（TCE）疗法详解 - 知乎
迎接TCE下一波浪潮_腾讯新闻
Janux Therapeutics on LinkedIn: Janux Therapeutics Announces Positive ...
Janux Therapeutics: Insider Spending Reflects Confidence in Biotech's ...
#clinicaltrials #prostatecancer #cancer #immunotherapy #tcells | Ted Benson
#mcrpc #janx #tcellengagers #cancer #oncology #immunotherapy # ...
Janux Therapeutics to Host Virtual Event Discussing Updated Phase 1a ...
Janux Therapeutics on LinkedIn: #janx #tcellengagers #cancer #oncology ...
An in-situ peptide-antibody self-assembly to block CD47 and CD24 ...
Janux Therapeutics (JANX): Strong Buy As Pipeline Advances, Stock ...
药物研发专栏｜三篇文章讲透Probody设计1：酶切依赖型激活的TCE前药平台 - 知乎
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Janux Therapeutics' CEO David Campbell reviews this week ...
Janux Therapeutics: Pioneering a New Era in Prostate Cancer Treatment ...
Rapid-Act T Cell Activation Kit (Mouse, Anti-CD3/CD28) | Cell Signaling ...
Janux | T Cell Immuno-oncology | Technology Platform
JANX007真的很拉垮吗？ - 知乎
slide4
1325 Preclinical activity and safety profile of JANX007, a novel PSMA ...
Janux's shares jump 130% as analysts see blockbuster potential in phase ...
Janux Announces Encouraging Efficacy and Safety Profile from Ongoing ...
Janux Therapeutics to Host Virtual Event Discussing Updated Clinical ...
迎接TCE下一波浪潮 文 | 氨基观察双抗方兴未艾之际，TCE已经卷到了四抗。日前， 复宏汉霖 宣布其自主研发的四抗HLX3901的IND申请 ...
迎接TCE下一波浪潮 双抗方兴未艾之际，TCE已经卷到了四抗。日前， 复宏汉霖 宣布其自主研发的四抗HLX3901的IND申请获NMPA批准 ...
